AR126701A1 - Derivados de n-ciclopropilpirido[4,3-d]pirimidin-4-amina y usos de los mismos - Google Patents
Derivados de n-ciclopropilpirido[4,3-d]pirimidin-4-amina y usos de los mismosInfo
- Publication number
- AR126701A1 AR126701A1 ARP220102213A ARP220102213A AR126701A1 AR 126701 A1 AR126701 A1 AR 126701A1 AR P220102213 A ARP220102213 A AR P220102213A AR P220102213 A ARP220102213 A AR P220102213A AR 126701 A1 AR126701 A1 AR 126701A1
- Authority
- AR
- Argentina
- Prior art keywords
- stereoisomer
- pharmaceutically acceptable
- acceptable salt
- cyclopropylpyride
- pyrimidin
- Prior art date
Links
- OYRRZWATULMEPF-UHFFFAOYSA-N pyrimidin-4-amine Chemical class NC1=CC=NC=N1 OYRRZWATULMEPF-UHFFFAOYSA-N 0.000 title 1
- 150000003839 salts Chemical class 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 3
- 239000000651 prodrug Substances 0.000 abstract 2
- 229940002612 prodrug Drugs 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La invención se relaciona con un compuesto de la fórmula (1B), un estereoisómero del mismo, una sal farmacéuticamente aceptable del mismo, una sal farmacéuticamente aceptable del estereoisómero del mismo, una prodroga del mismo, una molécula deuterada del mismo o una forma conjugada del mismo; composición que contiene el mismo y el uso del mismo. Reivindicación 43: Un uso del compuesto de la fórmula (1B), un estereoisómero del mismo, una sal farmacéuticamente aceptable del mismo, una sal farmacéuticamente aceptable del estereoisómero del mismo, una prodroga del mismo, una molécula deuterada del mismo o una forma conjugada del mismo de una cualquiera de las reivindicaciones 1 a 36, o la composición farmacéutica de la reivindicación 37 para el tratamiento de cáncer. Reivindicación 57: Un intermediario para preparar el compuesto de la fórmula (1B), que comprende una cualquiera de las siguientes fórmulas: del grupo de fórmulas (2).
Applications Claiming Priority (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2021113365 | 2021-08-18 | ||
| CN2021132066 | 2021-11-22 | ||
| CN2021132636 | 2021-11-24 | ||
| CN2021139165 | 2021-12-17 | ||
| CN2022072459 | 2022-01-18 | ||
| CN2022072926 | 2022-01-20 | ||
| CN2022074053 | 2022-01-26 | ||
| CN2022074165 | 2022-01-27 | ||
| CN2022077674 | 2022-02-24 | ||
| CN2022081602 | 2022-03-18 | ||
| CN2022083320 | 2022-03-28 | ||
| CN2022084317 | 2022-03-31 | ||
| CN2022087377 | 2022-04-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR126701A1 true AR126701A1 (es) | 2023-11-01 |
Family
ID=85240045
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220102213A AR126701A1 (es) | 2021-08-18 | 2022-08-17 | Derivados de n-ciclopropilpirido[4,3-d]pirimidin-4-amina y usos de los mismos |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240376128A1 (es) |
| EP (1) | EP4387971A1 (es) |
| CN (1) | CN117858878A (es) |
| AR (1) | AR126701A1 (es) |
| TW (1) | TW202325284A (es) |
| UY (1) | UY39904A (es) |
| WO (1) | WO2023020518A1 (es) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021106230A1 (ja) | 2019-11-29 | 2021-06-03 | 大鵬薬品工業株式会社 | 新規なフェノール化合物又はその塩 |
| JP2025510572A (ja) | 2022-03-08 | 2025-04-15 | レボリューション メディシンズ インコーポレイテッド | 免疫不応性肺癌を治療するための方法 |
| CN118900838A (zh) * | 2022-03-24 | 2024-11-05 | 百济神州有限公司 | 杂环化合物、其组合物及其治疗方法 |
| CN119998298A (zh) | 2022-06-10 | 2025-05-13 | 锐新医药公司 | 大环ras抑制剂 |
| WO2023246777A1 (en) * | 2022-06-20 | 2023-12-28 | Jacobio Pharmaceuticals Co., Ltd. | K-ras mutant protein inhibitors |
| US20260015363A1 (en) * | 2022-07-01 | 2026-01-15 | Suzhou Zelgen Biopharmaceuticals Co., Ltd. | Substituted pyrimidine-fused ring inhibitor, method for preparing same, and use thereof |
| WO2024083246A1 (en) * | 2022-10-21 | 2024-04-25 | Ascentage Pharma (Suzhou) Co., Ltd. | Kras inhibitors |
| WO2024104425A1 (zh) * | 2022-11-17 | 2024-05-23 | 广东东阳光药业股份有限公司 | 一种kras抑制剂化合物、其药物组合物及其用途 |
| AU2023385486A1 (en) | 2022-11-21 | 2025-06-05 | Treeline Biosciences, Inc. | Spirocyclic dihydropyranopyrimidine kras inhibitors |
| AU2024241633A1 (en) | 2023-03-30 | 2025-11-06 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| WO2024211712A1 (en) | 2023-04-07 | 2024-10-10 | Revolution Medicines, Inc. | Condensed macrocyclic compounds as ras inhibitors |
| AR132338A1 (es) | 2023-04-07 | 2025-06-18 | Revolution Medicines Inc | Inhibidores de ras |
| TW202448897A (zh) | 2023-04-14 | 2024-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑之結晶形式、含有其之組合物及其使用方法 |
| CN121100123A (zh) | 2023-04-14 | 2025-12-09 | 锐新医药公司 | Ras抑制剂的结晶形式 |
| WO2024229406A1 (en) | 2023-05-04 | 2024-11-07 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| WO2025034702A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Rmc-6291 for use in the treatment of ras protein-related disease or disorder |
| TW202515570A (zh) | 2023-08-17 | 2025-04-16 | 美商樹線生物科學公司 | 螺環二氫哌喃并嘧啶ｋｒａｓ抑制劑 |
| US20250109147A1 (en) | 2023-09-08 | 2025-04-03 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| TW202528315A (zh) | 2023-09-21 | 2025-07-16 | 美商樹線生物科學公司 | 螺環二氫哌喃并吡啶ＫＲａｓ抑制劑 |
| TW202530228A (zh) | 2023-10-12 | 2025-08-01 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| TW202535891A (zh) | 2023-10-20 | 2025-09-16 | 美商默沙東有限責任公司 | Ｋｒａｓ蛋白之小分子抑制劑 |
| WO2025151594A1 (en) * | 2024-01-09 | 2025-07-17 | Kestrel Therapeutics Inc. | Fused azines as ras inhibitors and methods of use thereof |
| WO2025148979A1 (zh) * | 2024-01-10 | 2025-07-17 | 南京明德新药研发有限公司 | 吡啶并嘧啶类衍生物的晶型、制备方法及其应用 |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025245127A1 (en) | 2024-05-21 | 2025-11-27 | Treeline Biosciences, Inc. | Spirocyclic dihydropyranopyrimidine kras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3556B1 (ar) * | 2014-09-18 | 2020-07-05 | Araxes Pharma Llc | علاجات مدمجة لمعالجة السرطان |
| EP3519402A1 (en) * | 2016-09-29 | 2019-08-07 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
| EP3630745A2 (en) * | 2017-05-25 | 2020-04-08 | Araxes Pharma LLC | Covalent inhibitors of kras |
| FI3735299T3 (fi) * | 2018-11-09 | 2024-12-04 | Hoffmann La Roche | Fuusioituja rengasyhdisteitä |
| EP3908283A4 (en) * | 2019-01-10 | 2022-10-12 | Mirati Therapeutics, Inc. | KRAS G12C INHIBITORS |
| WO2021106231A1 (en) * | 2019-11-29 | 2021-06-03 | Taiho Pharmaceutical Co., Ltd. | A compound having inhibitory activity against kras g12d mutation |
| US20230339976A1 (en) * | 2020-08-04 | 2023-10-26 | Mirati Therapeutics, Inc. | Kras g12d inhibitors |
| WO2022105855A1 (en) * | 2020-11-20 | 2022-05-27 | Jacobio Pharmaceuticals Co., Ltd. | Kras g12d inhibitors |
| AU2021401232A1 (en) * | 2020-12-15 | 2023-06-22 | Mirati Therapeutics, Inc. | Azaquinazoline pan-kras inhibitors |
-
2022
- 2022-08-17 EP EP22857829.0A patent/EP4387971A1/en not_active Withdrawn
- 2022-08-17 CN CN202280056400.7A patent/CN117858878A/zh active Pending
- 2022-08-17 TW TW111130947A patent/TW202325284A/zh unknown
- 2022-08-17 US US18/684,203 patent/US20240376128A1/en active Pending
- 2022-08-17 WO PCT/CN2022/112918 patent/WO2023020518A1/en not_active Ceased
- 2022-08-17 UY UY0001039904A patent/UY39904A/es unknown
- 2022-08-17 AR ARP220102213A patent/AR126701A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4387971A1 (en) | 2024-06-26 |
| WO2023020518A1 (en) | 2023-02-23 |
| CN117858878A (zh) | 2024-04-09 |
| TW202325284A (zh) | 2023-07-01 |
| US20240376128A1 (en) | 2024-11-14 |
| UY39904A (es) | 2023-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR126701A1 (es) | Derivados de n-ciclopropilpirido[4,3-d]pirimidin-4-amina y usos de los mismos | |
| UY39906A (es) | Derivados de 1,4-oxazepano y usos de los mismos | |
| CL2022000271A1 (es) | Inhibidores de la fosfatasa shp2 de pirazolo(3,4-b)pirazina. | |
| CR20220281A (es) | Derivados de pirazolilo útiles como agentes anti-cancerígenos | |
| PE20212303A1 (es) | Inhibidores aza-heterobiciclicos de mat2a y metodos de uso en el tratamiento de cancer | |
| CL2019001077A1 (es) | Derivados de 6,7,8,9-tetrahidro-3h-pirazolo[4,3-f] isoquinolina útiles en el tratamiento del cáncer. | |
| CL2025001072A1 (es) | Compuestos tricíclicos; composición farmacéutica; uso para tratar cáncer. | |
| AR056873A1 (es) | Derivados de pirazolopirimidinas como inhibidores de quinasa dependientes de ciclina, composiciones farmaceuticas | |
| AR108046A1 (es) | Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue | |
| CL2023003223A1 (es) | Derivado de fosfonilo, y composición y aplicación farmacéutica de este | |
| MX2024014401A (es) | Inhibidor de parp que es un derivado biciclico y uso de este | |
| CL2024001565A1 (es) | Compuestos macrocíclicos con actividad inhibidora de la farnesiltransferasa, composición que los comprende y su uso. | |
| UY39625A (es) | Derivados tricíclicos útiles como inhibidores de parp7 | |
| ECSP034494A (es) | Inhibidores novedosos de la farnesil proteino trasferasa como agentes antitumorales | |
| MX2024012471A (es) | Inhibidores de cinasas dependientes de ciclina 9 (cdk9) | |
| MX2025002817A (es) | Compuestos para el tratamiento del cancer | |
| CL2025000161A1 (es) | Compuestos cíclicos y métodos de utilización de estos. | |
| DOP2022000073A (es) | Derivados de 2-azaspiro[3,4]octano como agonistas de m4 | |
| DOP2025000099A (es) | Enlazadores-cargas útiles de adc derivados de exatecán, composiciones farmacéuticas, y usos de los mismos | |
| CR20240216A (es) | Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno | |
| PA8474401A1 (es) | 3-ceto derivados triciclicos de 6-0-metileritromicina | |
| UY28387A1 (es) | Compuestos novedosos | |
| AR129171A1 (es) | Compuestos heteroaromáticos | |
| CL2025001739A1 (es) | Enlazadores-cargas útiles de auristatina, composiciones farmacéuticas, y usos de los mismos. | |
| AR131335A1 (es) | Enlazadores-cargas útiles de auristatina, composiciones farmacéuticas, y usos de los mismos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |